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erythropoietin treatment, while in the first 12 months after the bid 3647 patients, 
resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients 
received colony-stimulating factor treatment, while in the first 12 months after the 
bid 13352 patients, resulting in a 4.5% decline. ConClusions: The analyses of the 
Hungarian price competition bid of biosimilar products showed a minimal decline 
in the number of patients under treatment by both colony-stimulating factor and 
erythropoietin products while the health insurance reimbursement of these drugs 
significantly decreased.
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objeCtives: Prior authorization (PA) restrictions have been implemented by US 
health plans in an effort to ensure safety, manage appropriate utilization and control 
costs. A review of published peer-reviewed literature was conducted to evaluate 
the impact of such PA restrictions on resource utilization and costs. Methods: A 
targeted review of literature was conducted in Medline from 2009 onwards using 
search terms including “prior authorization”, “resource”, “use”, “utilization”, “cost”, 
“impact”, “economic”. Review articles, non-English language studies, non-US stud-
ies, kins, and studies evaluating the effectiveness of formulary policies of which PA 
may be a component were excluded. Impact of PA policies on health care utilization 
and costs was qualitatively assessed. Results: Fourteen studies were identified 
which met our inclusion criteria. Majority (57%) of the studies were conducted on 
Medicaid plans (Medicaid: 8, commercial: 4, Medicare: 1, not clear: 1). Majority (57%) 
of studies evaluated the impact of mental health medications (anti-convulsants, 
anti-depressants bipolar medications, antipsychotics), two studies were conducted 
on anti-diabetics, one on a multiple sclerosis drug, one for a lipid-lowering drug, 
one on an anti-hypertensive and one on a vaccine. Four studies were industry-
sponsored. 12 studies were retrospective data analyses and only 2 studies were 
decision-analytic models. Overall, the trend showed that PA restrictions were effec-
tive in reducing pharmacy utilization and health care costs, but few studies also 
raised concerns on patient safety and quality of care outcomes due to PA poli-
cies. ConClusions: Although PA restrictions may result in cost-savings, patient 
safety and quality of life concerns must also be evaluated while imposing these 
restrictions. Rigorously designed studies including assesment of PA administration 
costs as well as indirect costs due to lost productivity should be conducted to better 
assess the overall economic impact of such restrictions.
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objeCtives: The objective is to test the hypothesis whether NICE recommendations 
on the use of a new drug affect recommendations from other bodies in countries 
outside England and Wales. To our knowledge, this is the first attempt to approach 
this topic quantitatively. Therefore, a sub-objective is to determine the feasibility 
of gathering a high quality database with sufficient number of observations to 
test our hypothesis. Methods: A basket of 29 drug/indication pairs and a group 
of 15 countries were included (Australia, Canada, Denmark, France, Italy, Korea, 
The Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia, Ecuador, Egypt and 
Ghana). Information regarding NICE HTA recommendations was extracted from 
NICE’s website and HTAinSite. com. Moreover, an online-survey of key opinion lead-
ers was carried out to collect information regarding the HTA decision in 10 coun-
tries. For the remaining five countries, we used the information from their official 
webpages. A descriptive analysis was conducted, including an examination of the 
position of each decision of NICE in comparison with that of other HTA agencies in 
the timeline of decision making about the 29 medicines. Results: There is a lack 
of comparability between the publically available information. The findings suggest 
that after the publication of a NICE appraisal there is a higher probability that an 
HTA is undertaken for the same drug in other countries. Furthermore, when NICE 
has published a negative decision, the tendency of not recommending the drug by 
another HTA body is much larger after than before NICE’s decision. ConClusions: 
Issues encountered in the collection of information made it difficult to quantify the 
effect of NICE recommendations on HTA decisions in other countries. The results 
suggest that the selected agencies are considering NICE decisions as a factor for 
rejecting or restricting the use of drugs which in other case would be recommended 
or reimbursed.
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objeCtives: Little information is available on complication-related resource utiliza-
tion and costs over time in patients with complex abdominal wall reconstruction. 
Under pay-for-performance requirements financial decision-makers need better 
information to allocate health care resources and budget dollars. This analysis 
reports complication-related resource utilization and costs over time in a real-world 
patient population undergoing complex abdominal wall reconstruction. Methods: 
A cohort of patients with complex abdominal wall reconstructions during inpa-
tient stays between1/1/08 and 6/30/11 (Index event) were followed for 12 months. 
Related complications, returns for facility-based care and related costs were evalu-
ated for 30-60-90-365 days after discharge. Insurance claims from the Truven Health 
each country’s department of health. Countries were reviewed under a range of 
headings including: current delivery models in place, institutions responsible for 
delivery and organisation of reimbursement system, incentive structures in place, 
basic bundle of health care covered, additional options for coverage, disease-specific 
resource use and health outcomes, government contribution to cost of health care 
and overall health care expenditure. Results: Generally, the basic bundle of health 
care across countries with Universal entitlement ensures comprehensive medi-
cal care for everyone including GP services, access to tertiary care, post-natal care 
and medications. Co-payments, excess payments and retention fees apply in some 
countries dependent upon the Universal delivery model in place. ConClusions: 
This review presents characteristics of Universal health care delivery systems across 
Europe. Basic bundles of health care provision and organisation of reimbursement 
across delivery models have been outlined, thus providing further clarity on the 
characteristics of and variation across Universal health care models.
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objeCtives: By 2013 all European Union (EU) member states were recommended 
to elaborate and adopt a national strategy for rare diseases. This study provides 
insights into the national rare disease strategies, in particular about the status of the 
programmes, recent developments, and the congruencies and differences between 
the programmes regarding market access. Methods: A literature and Internet 
search was performed to identify national strategies for rare diseases published by 
EU member states. Both policies and recent orphan drug introductions have been 
analysed to compare the rare disease strategies. Results: All member states had a 
variety of approaches already in place before developing a national strategy. France 
is the frontrunner in implementing rare disease policies as well as the member 
state with the highest number of marketed orphan drugs. Over the past five years, 
most member states finalised their national plans with a peak in publications late 
2013. Plans include similar methods on increasing patient access such as off-label 
use, compassionate drug use and utilising cross-border health care. Member states 
with a decentralised market access model (e.g., Spain and Italy) commonly use 
national funds and decision-making to provide equity in treatment levels across 
the nation for rare diseases. There are few orphan drug specific pricing policies; 
however special reimbursement criteria are common especially in countries with 
cost-effectiveness criteria. ConClusions: Increasing patient access to orphan 
drugs has been a focus point in the national plans for rare diseases. Congruencies 
in methods will aid the EU’s ambition to align policies at European level. However 
the implementation phase has only recently been initiated for most plans and actual 
policies are yet to be developed. As member states such as France are introducing 
cost-effectiveness criteria in their health technology assessments, one can expect 
that tailored criteria need to be developed for orphan drug assessments.
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objeCtives: Hospitals are important cost elements of the Hungarian health care 
system. During the past decade, several health care reform affected the number 
of hospital beds in Hungary. The aim of our research is to analyse the efficiency 
of the Hungarian acute inpatient-care system. Methods: Data derived from 
the Hungarian nationwide health insurance database. We analyzed the techni-
cal- (TE) and scale efficiency (SE) of the Hungarian acute inpatient-care system 
(2003, 2006, 2010). The number of hospitals included into the study was 133 in 
2003,125 in 2006 and 93 in 2010. We chose four inputs and two outputs: the number 
of active hospital beds, the number of discharged patients, the number of one-
day cases, completed days of nursing (inputs), average length of stay, DRG cost 
weights (outputs). The method we used for our calculations was Data Envelopment 
Analysis. Results: In 2003 both the technical and scale efficiency were high 
(TE: 96.9%; SE: 92.9%). To 2006 the situation deteriorated by some degree (TE: 96.6%; 
SE: 80.3%). By 2010 technical efficiency still did not show improvement (TE: 94.0%), 
but scale efficiency increased (SE: 88.2%). Usually the hospitals with higher number 
of beds are more efficient than the smaller units. ConClusions: The effects of the 
performance volume limit did not improve the two values; however, the capacity 
decrease of 2007 did improve the scale efficiency to some extent. The Hungarian 
health care system needs to reduce the numbers of hospitals and rethink their 
functions, but needs to improve the size of them.
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objeCtives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of colony-stimulating factor 
and erythropoietin products. Methods: Data derived from the nationwide phar-
maceutical database of Hungarian National Health Insurance Fund Administration. 
We analysed how the number of patients treated by colony-stimulating fac-
tor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and 
after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in 
Hungary. Results: In the 12 months before biosimilar bid 4167 patients received 
